Microsoft: A Dividend Growth Giant


Image Source: Microsoft

Microsoft is no longer a tech dinosaur. Estimates suggest it is beating Amazon at its own game. We’re huge fans of Microsoft’s free cash flow generation and balance-sheet health and what that means for the dividend. There’s not a lot to dislike about Microsoft, and while the risks are many, few company’s have a stronger business model.

Mutual Fund Tragedy, ROE, and the Time Horizon

Comparisons between growth versus value stocks may never go away, but President of Investment Research Brian Nelson explains why you should know better than to think stocks can easily be divided up as such. He talks about this, as well as the pitfalls of ROE (return on equity) and how to think about the time horizon. Running time: ~10 minutes.

Nelson: Is Visa the Best Company Ever?


Image Source: Visa’s fiscal fourth-quarter 2017 earnings slide deck

Visa’s business model is phenomenal and its competitive advantages among the best in the world. The company’s free cash flow generation is remarkable, and it alone covers its cash dividend payment by more than 5 times. There are few companies with higher levels of profitability than Visa’s, and even fewer that also have as strong of growth potential. The company’s valuation is starting to get a little stretched, but it has the free-cash-flow generation to grow into it.

Admit It: You Know Nothing About the Dividend

President of Investment Research Brian Nelson talks about how the concept of a dividend is completely miscontrued due to societal and cultural reasons, but he also explains why he likes dividends. Warning: He’s going to bust out Monopoly pieces. You don’t want to miss this! Running time: ~15 minutes.

The Fed’s Dislocation and Too Few Stocks?

President of Investment Research Brian Nelson talks about how central banks may be pushing savers into riskier assets than what might otherwise be warranted by their risk profiles, how interest rates should be viewed within the valuation context, and whether too few stocks to invest in is driving a ‘rising tide lifts all boats’ dynamic. A discussion about the severe limitations of the price-to-earnings ratio is included. Running time: ~14 minutes.

2018 Healthcare and Biotech Outlook


Image Source: Global Panorama

2017 will undoubtedly go down as one of the most fabulous years for the stock market, and while we continue to warn of the dangers associated with the market continuing to trade at lofty valuations, we are intrigued by the outlook for big cap pharma and biotech in the near term. Changes in the US tax laws will likely have a profound impact on the industry.